Talis Biomedical Corporation

NasdaqCM:TLIS Stock Report

Market Cap: US$15.7m

Talis Biomedical Past Earnings Performance

Past criteria checks 0/6

Talis Biomedical's earnings have been declining at an average annual rate of -13.4%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 19.2% per year.

Key information

-13.4%

Earnings growth rate

25.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-19.2%
Return on equity-89.7%
Net Margin-2,905.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Aug 16
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Talis Biomedical reports Q2 results

Aug 02

Talis Biomedical Aims For Manufacturing Turnaround

Mar 17

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Feb 08
Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18
News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14
Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Revenue & Expenses Breakdown
Beta

How Talis Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:TLIS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232-62250
30 Sep 232-7526-23
30 Jun 233-86290
31 Mar 233-98320
31 Dec 225-113370
30 Sep 225-1154255
30 Jun 225-127460
31 Mar 224-165470
31 Dec 218-192420
30 Sep 218-208350
30 Jun 2117-199260
31 Mar 2118-144180
31 Dec 2011-91130
30 Sep 2012-1100
31 Dec 1942670
31 Dec 182-2150

Quality Earnings: TLIS is currently unprofitable.

Growing Profit Margin: TLIS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TLIS is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.

Accelerating Growth: Unable to compare TLIS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLIS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).


Return on Equity

High ROE: TLIS has a negative Return on Equity (-89.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.